tirzepatide bimagrumab A drug called apitegromab may help to preserve lean body mass during weight loss with tirzepatide, a GLP-1 receptor agonist, according to a phase 2 clinical trial published in Nature Medicine. The Lilly Cuts Mid-Stage Obesity Study

The approval was based on the SURMOUNT clinical trial program, which enrolled over 4,500 participants and demonstrated consistent, dose-dependent weight reductions across diverse populations

Insurance Support : Benefit from verified claims and handled prior authorizations

Anyone wishing to participate in a clinical trial of retatrutide should discuss this with their GP or specialist, or search for registered studies at clinicaltrials.gov or the MHRA Clinical Trials register

adults reported taking a GLP-1 drug, with about 38% of those (about 2.3% total) taking the drug to address excess weight (Montero et al., 2024)